LAPTM4B and posterior cortical atrophy: This raises the possibility that LAPTM4B-35 may be a prognostic parameter for PCa that is as or more reliable than the clinicopathologic factors currently in use and suggests the possibility to use LAPTM4B-35 in individualization of both patient prognosis and therapy.